SPOP
SPOP (Speckle-type POZ protein) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer, Endometrial cancer, Non-Hodgkin lymphoma and 4 more.
Overview
Component of a cullin-RING-based BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex that mediates the ubiquitination of target proteins, leading most often to their proteasomal degradation. In complex with CUL3, involved in ubiquitination and proteasomal degradation of BRMS1, DAXX, PDX1/IPF1, GLI2 and GLI3. In complex with CUL3, involved in ubiquitination of MACROH2A1 and BMI1; this does not lead to their proteasomal degradation.
CIViC holds 9 clinical evidence items and 0 assertions across 10 variants. Open Targets scores its association with cancer at 0.77 (direct and indirect evidence; datatypes literature 1.00, genetic association 0.00, somatic mutation 0.92). IntOGen calls it a driver in 15 cohorts (14 activating, 1 loss-of-function), covering Non-Hodgkin Lymphoma, Prostate Adenocarcinoma, Prostate, Endometrial Carcinoma, Uterine Carcinosarcoma/Uterine Malignant Mixed Mullerian Tumour.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · SPOP (Speckle-type POZ protein) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer, Endometrial cancer, Non-Hodgkin lymphoma and 4 more.
- 1 · What it is
SPOP (Speckle-type POZ protein) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer, Endometrial cancer, Non-Hodgkin lymphoma and 4 more.
- 2 · What goes wrong in cancer
Component of a cullin-RING-based BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex that mediates the ubiquitination of target proteins, leading most often to their proteasomal degradation.
- 3 · How drugs use it
No product in this corpus aims at SPOP yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:11254 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O43791 (protein name, function text, keywords and locations (REST API)); CIViC gene SPOP (9 evidence items, 0 assertions, 10 variants; diseases: (GraphQL API, CC0)); Open Targets ENSG00000121067 (association with cancer (MONDO_0004992) 0.77; per-cancer scores at or above 0.5: prostate cancer 0.72, ovarian cancer 0.52, endometrial cancer 0.62, melanoma 0.52, skin cancer 0.52 (GraphQL API, CC0)); IntOGen SPOP (driver in 15 cohorts (Act 14, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Component of a cullin-RING-based BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex that mediates the ubiquitination of target proteins, leading most often to their proteasomal degradation. In complex with CUL3, involved in ubiquitination and proteasomal degradation of BRMS1, DAXX, PDX1/IPF1, GLI2 and GLI3. In complex with CUL3, involved in ubiquitination of MACROH2A1 and BMI1; this does not lead to their proteasomal degradation. Inhibits transcriptional activation of PDX1/IPF1 targets, such as insulin, by promoting PDX1/IPF1 degradation. The cullin-RING-based BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex containing homodimeric SPOP has higher ubiquitin ligase activity than the complex that contains the heterodimer formed by SPOP and SPOPL. Involved in the regulation of bromodomain and extra-terminal motif (BET) proteins BRD2, BRD3, BRD4 stability. Location: Nucleus; Nucleus speckle; Cytoplasm (UniProt). Locus 17q21.33 (HGNC).
- Prostate cancer: Open Targets association 0.72 with prostate cancer (MONDO_0008315); IntOGen driver in 12 cohorts (PRAD, PROSTATE)
- Endometrial cancer: Open Targets association 0.62 with endometrial cancer (MONDO_0011962); IntOGen driver in 1 cohort (UCEC)
- Non-Hodgkin lymphoma: IntOGen driver in 1 cohort (NHL)
- Ovarian cancer: Open Targets association 0.52 with ovarian cancer (MONDO_0008170)
- Skin cancer: Open Targets association 0.52 with skin cancer (MONDO_0002898)
- Uterine carcinosarcoma: IntOGen driver in 1 cohort (UCS)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 14 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 9 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"SPOP" OR ABSTRACT:"SPOP" OR TITLE:"speckle type BTB/POZ protein" OR ABSTRACT:"speckle type BTB/POZ protein" OR TITLE:"Speckle-type POZ protein" OR ABSTRACT:"Speckle-type POZ protein" OR TITLE:"TEF2" OR ABSTRACT:"TEF2" OR TITLE:"BTBD32" OR ABSTRACT:"BTBD32") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SPOP, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetBCLAF1
Shares Uterine carcinosarcoma, IntOGen, Melanoma, Prostate cancer.
- TargetHIP1
Shares Uterine carcinosarcoma, Skin cancer (all types), IntOGen, Open Targets Platform.
- TargetWNT1
Shares Uterine carcinosarcoma, IntOGen.
- TargetZBTB7B
Shares Uterine carcinosarcoma, IntOGen.
- TargetFAM135B
Shares Uterine carcinosarcoma, Endometrial cancer, IntOGen.
- TrialZiv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
Shares Uterine carcinosarcoma, Ovarian cancer.
- IdeaHER2 ADCs as standard for HER2-positive serous endometrial cancer
Shares Uterine carcinosarcoma, Endometrial cancer.
- TermHysterectomy
Shares Uterine carcinosarcoma, Endometrial cancer.